Profound Medical Corp.
TSX:PRN.TO · Toronto Stock Exchange
+$0.11 today
Vol 0.00M · Avg 0.01M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
TSX:PRN.TO · Revenue to Net Income
Key Ratios
Analysis
$18.8M of revenue converted into -$38.8M of net income for the selected period. Gross margin is 71.5% and net margin is -282.4%, showing how much revenue survives after costs and taxes. EPS is $-1.24, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $16.4M +53.4% | $10.7M +48.4% | $7.2M +7.8% | $6.7M -2.8% | $6.9M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $4.8M +31.4% | $3.6M +29.3% | $2.8M -23.0% | $3.7M -6.7% | $3.9M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $11.6M +64.7% | $7.0M +60.6% | $4.4M +45.1% | $3.0M +2.3% | $3.0M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 70.8% +4.9pp | 65.9% +5.0pp | 60.9% +15.7pp | 45.2% +2.3pp | 43.0% | 9.8% | 28.9% | 38.3% |
| Research & Development | $21.0M +23.5% | $17.0M +18.0% | $14.4M -2.1% | $14.7M -3.8% | $15.3M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $32.6M +41.0% | $23.1M +24.2% | $18.6M +3.8% | $17.9M -0.2% | $18.0M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $53.6M +33.6% | $40.1M +21.5% | $33.0M +1.1% | $32.6M -1.9% | $33.2M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $569.8K -39.1% | $936.0K +0.8% | $929.0K -42.1% | $1.6M -14.6% | $1.9M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$41.4M -28.9% | -$32.1M -19.0% | -$27.0M -1.5% | -$26.6M +7.1% | -$28.6M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -252.8% +48.0pp | -300.8% +74.2pp | -375.0% +23.2pp | -398.2% +18.6pp | -416.8% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$42.0M -27.0% | -$33.1M -15.5% | -$28.6M +3.3% | -$29.6M +2.3% | -$30.3M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -256.3% +53.3pp | -309.6% +87.9pp | -397.5% +45.6pp | -443.1% -2.4pp | -440.7% | 16.6% | 24.1% | 22.0% |
| Interest Income | $1.1M -24.2% | $1.4M -12.5% | $1.6M +54.8% | $1.1M +417.3% | $205.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 | $0 -100.0% | $770.0K +356.1% | $168.8K +152.0% | $67.0K | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$1.1M -120.6% | $5.2M +2522.0% | $200.0K -83.6% | $1.2M +502.6% | -$303.0K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$43.1M -54.8% | -$27.8M +3.1% | -$28.7M -1.1% | -$28.4M +7.2% | -$30.6M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -262.9% -2.4pp | -260.5% +138.2pp | -398.6% +26.2pp | -424.8% +20.3pp | -445.1% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $256.4K +12920.5% | -$2.0K +98.4% | -$128.0K -144.6% | $287.0K +173.3% | $105.0K | $1.3B | -$1.6B | $745.2M |
| Net Income | -$43.3M -55.7% | -$27.8M +2.6% | -$28.6M +0.3% | -$28.7M +6.6% | -$30.7M | $4.9B | $4.8B | $4.7B |
| Net Margin | -264.4% -4.0pp | -260.4% +136.4pp | -396.8% +32.3pp | -429.1% +17.5pp | -446.7% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$1 -27.7% | -$1 +17.0% | -$1 +2.2% | -$1 +8.0% | -$2 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$1 -27.7% | -$1 +17.0% | -$1 +2.2% | -$1 +8.0% | -$2 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $30.2M +22.1% | $24.8M +16.9% | $21.2M +2.0% | $20.8M +1.5% | $20.5M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $30.2M +22.1% | $24.8M +16.9% | $21.2M +2.0% | $20.8M +1.5% | $20.5M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
NervGen Pharma Corp.
NGEN.V
$407.94M
Eupraxia Pharmaceuticals Inc.
TSX:EPRX.TO
$325.95M
Medical Facilities Corporation
TSX:DR.TO
$315.55M
Auxly Cannabis Group Inc.
TSX:XLY.TO
$250.54M
Quipt Home Medical Corp.
QIPT.TO
$221.44M
CareRx Corporation
TSX:CRRX.TO
$203.03M
Cybin Inc.
CYBN.NE
$154.92M
HLS Therapeutics Inc.
TSX:HLS.TO
$133.86M
Jushi Holdings Inc.
JUSH.CN
$133.80M
VentriPoint Diagnostics Ltd.
VPT.V
$22.52M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does PRN.TO generate?
Profound Medical Corp. (PRN.TO) reported $16.38M of revenue in fiscal 2025.
Is PRN.TO profitable?
Profound Medical Corp. (PRN.TO) reported -$43,315,210.00 of net income, with a net margin of -264.4%.
Explore More
Continue the stock analysis
Jump to another research area for this company.